Rasio cepet Assertio Holdings (ASRT)

Assertio Holdings, Inc. (ASRT) grows its business by acquiring FDA-approved drugs and optimizing expenses by eliminating redundant staff. Profitability depends on patent expiration dates and the success of new deals, with the current metric standing at 1.58. The absence of foreign trade risks due to operating exclusively in the US underscores the market trend for this pharmaceutical company's asset as reflected in this price chart.

The quick ratio measures the ability of Assertio Holdings, Inc. to instantaneously settle short-term debts using cash and accounts receivable, completely excluding illiquid inventory from the calculation. By analyzing the quick liquidity level, an investor assesses the real solvency of Assertio Holdings, Inc., which is critical when scaling acquired brands amid inelastic demand for neurological drugs.